Table 3

From: Tumor mica status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer

Characteristics		Number	Constituent ratio
Sex	Male	66	69.5%
	Female	29	30.5%
Age	<65	67	70.5%
	≥65	28	29.5%
Histological grade	G1-G2	48	50.5%
	G3-G4	47	49.5%
Stage	II	44	46.3%
	III	51	53.7%
Adjuvant Chemotherapy	Xelox, Folfox4	57	60.0%
	PF	38	40.0%
CIK cycles	<5	54	56.9%
	≥5	41	43.2%

Back to article page